Khairuddin Memon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11217090/publications.pdf

Version: 2024-02-01

24 papers	2,253 citations	394421 19 h-index	677142 22 g-index
24 all docs	24 docs citations	24 times ranked	2264 citing authors

#	Article	IF	Citations
1	Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. European Journal of Radiology, 2017, 93, 100-106.	2.6	30
2	Perfusion Reduction at Transcatheter Intraarterial Perfusion MR Imaging: A Promising Intraprocedural Biomarker to Predict Transplant-Free Survival during Chemoembolization of Hepatocellular Carcinoma. Radiology, 2014, 272, 587-597.	7.3	17
3	Hepatic yttrium-90 radioembolization for metastatic melanoma. Melanoma Research, 2014, 24, 244-251.	1.2	23
4	Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 486-493.	6.4	21
5	Comparative Study of Staging Systems for Hepatocellular Carcinoma in 428 Patients Treated with Radioembolization. Journal of Vascular and Interventional Radiology, 2014, 25, 1056-1066.	0.5	20
6	Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression. Journal of Hepatology, 2013, 58, 73-80.	3.7	110
7	Embolic Therapies. , 2013, , 101-113.		0
8	Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. Journal of Hepatology, 2013, 59, 1029-1036.	3.7	215
9	Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization. Clinical Gastroenterology and Hepatology, 2013, 11, 1358-1365.e1.	4.4	220
10	Yttrium-90 Radioembolization for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts. Journal of Vascular and Interventional Radiology, 2013, 24, 74-80.	0.5	21
11	Cancer Concepts and Principles: Primer for the Interventional Oncologistâ€”Part II. Journal of Vascular and Interventional Radiology, 2013, 24, 1167-1188.	0.5	26
12	Prospective Evaluation of Patients with Early-/Intermediate-stage Hepatocellular Carcinoma with Disease Progression Following Arterial Locoregional Therapy: Candidacy for Systemic Treatment or Clinical Trials. Journal of Vascular and Interventional Radiology, 2013, 24, 1189-1197.e2.	0.5	18
13	Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 Â± sorafenib. Hepatology, 2013, 58, 1655-1666.	7.3	66
14	Yttrium 90 Microspheres for the Treatment of Hepatocellular Carcinoma. Recent Results in Cancer Research, 2013, 190, 207-224.	1.8	28
15	Chemoembolization and Radioembolization in the Treatment of Primary Liver Cancers. , 2013, , 327-338.		0
16	Chemoembolization and Radioembolization for Metastatic Disease to the Liver: Available Data and Future Studies. Current Treatment Options in Oncology, 2012, 13, 403-415.	3.0	38
17	Radioembolization for Neuroendocrine Liver Metastases: Safety, Imaging, and Long-Term Outcomes. International Journal of Radiation Oncology Biology Physics, 2012, 83, 887-894.	0.8	137
18	Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis. Journal of Hepatology, 2012, 56, 1112-1120.	3.7	82

#	Article	IF	Citations
19	Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: Analyzing patterns of progression in 285 patients. Hepatology, 2012, 55, 1432-1442.	7.3	64
20	Research Reporting Standards for Radioembolization of Hepatic Malignancies. Journal of Vascular and Interventional Radiology, 2011, 22, 265-278.	0.5	185
21	Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 497-507.e2.	1.3	566
22	Radiographic Response to Locoregional Therapy in Hepatocellular Carcinoma Predicts Patient Survival Times. Gastroenterology, 2011, 141, 526-535.e2.	1.3	148
23	Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologicâ€“pathologic correlation. Journal of Hepatology, 2011, 54, 695-704.	3.7	140
24	Radioembolization for Primary and Metastatic Liver Cancer. Seminars in Radiation Oncology, 2011, 21, 294-302.	2.2	78